Analysis of iron homeostasis and erythroid activity in a cohort of low-risk myelodysplastic patients

被引：0
|
作者：
Messa, E. [1 ]
Maffe, C. [1 ]
Volpe, G. [1 ]
Campostrini, N. [2 ]
Gioia, D. [3 ]
Carturan, S. [1 ]
Zanone, C. [1 ]
Levis, A. [3 ]
Cilloni, D. [1 ]
Girelli, D. [2 ]
Camaschella, C. [4 ]
Saglio, G. [1 ]
机构：
[1] Univ Turin, Orbassano, Italy
[2] Univ Verona, I-37100 Verona, Italy
[3] SS Arrigo & Biagio Hosp, Alessandria, Italy
[4] S Raffaele Inst, Milan, Italy
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70167-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S108 / S109
页数：2
相关论文
共 50 条
  • [41] LOW-RISK MYELODYSPLASTIC PATIENTS SUPPORTED WITH ERYTHROPOIETIN PLUS LIPOSOMIAL IRON SHOWS A REDUCED NUMBER OF FEBRILE EPISODES THAN PATIENTS WITH INTRAVENOUS IRON SUPPORT.
    Giordano, G.
    D'Amico, F.
    Commatteo, A.
    Berardi, G.
    Berardi, D.
    Carabellese, B.
    Gigli, R.
    Magri, M.
    Licianci, A.
    di Marzio, L.
    HAEMATOLOGICA, 2015, 100 : 472 - 473
  • [42] IMPACT OF IRON OVERLOAD AND POTENTIAL BENEFIT FROM IRON CHELATION IN LOW-RISK MYELODYSPLASTIC SYNDROME AND BEFORE AND AFTER BMT
    Rachmilewitz, Eliezer
    LEUKEMIA RESEARCH, 2014, 38 : S2 - S2
  • [43] Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes
    Gianelli, Umberto
    Fracchiolla, Nicola Stefano
    Cortelezzi, Agostino
    Pellegrini, Caterina
    Savi, Federica
    Moro, Alessia
    Grimoldi, Maria Grazia
    Deliliers, Giorgio Lambertenghi
    Coggi, Guido
    Bosari, Silvano
    ANNALS OF HEMATOLOGY, 2007, 86 (03) : 185 - 189
  • [44] Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromes
    Umberto Gianelli
    Nicola Stefano Fracchiolla
    Agostino Cortelezzi
    Caterina Pellegrini
    Federica Savi
    Alessia Moro
    Maria Grazia Grimoldi
    Giorgio Lambertenghi Deliliers
    Guido Coggi
    Silvano Bosari
    Annals of Hematology, 2007, 86 : 185 - 189
  • [45] Evidence of polyclonal hematopoiesis in a large proportion of patients with low-risk myelodysplastic syndrome.
    Malcovati, L
    Della Porta, MG
    Galli, A
    Boggi, S
    Malabarba, L
    Pietra, D
    Passamonti, F
    Bergamaschi, G
    Lazzarino, M
    Cazzola, M
    BLOOD, 2004, 104 (11) : 649A - 650A
  • [46] Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept
    Fattizzo, Bruno
    Marchetti, Alfredo
    Zaninoni, Anna
    Lionetti, Marta
    Riva, Marta
    Rizzo, Lorenzo
    Pettine, Loredana
    Galli, Nicole
    Mazzon, Federico
    Fermo, Elisa
    Maeda, Akihiro
    Marella, Alessio
    Da Via, Matteo Claudio
    Passamonti, Francesco
    Bolli, Niccolo
    Barcellini, Wilma
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : E345 - E348
  • [47] Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome
    Novotna, Bozena
    Bagryantseva, Yana
    Siskova, Magda
    Neuwirtova, Radana
    LEUKEMIA RESEARCH, 2009, 33 (02) : 340 - 343
  • [48] Impact of Erythropoietic Stimulating Agents on Mutational Composition in Patients with Low-Risk Myelodysplastic Syndromes
    Patel, Bhumika
    Saygin, Caner
    Przychodzen, Bartlomiej P.
    Kuzmanovic, Teodora
    Hirsch, Cassandra M.
    Clemente, Michael J.
    Thota, Swapna
    Nazha, Aziz
    Mikkael, Sekeres A.
    Maciejewski, Jaroslaw P.
    Carraway, Hetty E.
    BLOOD, 2016, 128 (22)
  • [49] MUTATIONAL PROFILE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME AT THE TIME OF PROGRESSION TO ACUTE LEUKEMIA
    Pedrote, B.
    Falantes, J. F.
    Carrillo, E.
    Calderon-Cabrera, C.
    Espigado, I
    Perez-Simon, J. A.
    HAEMATOLOGICA, 2019, 104 : 182 - 182
  • [50] Clinical responses to alemtuzumab in six patients with low-risk myelodysplastic syndromes and aplastic anemia
    Neukirchen, J.
    Strupp, C.
    Kuendgen, A.
    Tsamaloukas, A.
    Haas, R.
    Germing, U.
    ONKOLOGIE, 2012, 35 : 148 - 149
12345